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It is generally recognized that long-term survivors of childhood cancer are at a substantially increased risk of developing second malignant neoplasms (SMN) at a broad spectrum of anatomic sites following exposure to chemotherapy and radiotherapy [1] [2] [3] [4] [5] The importance of genetic factors must also be considered [6] [7] . Unlike leukemia, solid tumors generally occur much later following treatment of the first malignancy 8 . Pediatric survivors experience significantly increased risk of cancers of the female breast, thyroid, digestive tract, lung, bone and connective tissue [9] [10] .
However, digestive system cancers account for about half of the cancers in excess diagnosed in atomic bomb survivors 11 , and thus might also be the case in survivors of childhood cancer. The etiology and risk factors are incompletely understood, but often include chemotherapy agents and ionizing radiation, while the risk increases with increasing follow-up after radiation and if exposure occurred at a young age [12] [13] .
Risk of colorectal cancers was shown not to increase until 10 years after the diagnosis of childhood Hodgkin's disease and remained elevated for at least a decade, suggesting late radiogenic effects 14 , although data are currently insufficient to ascertain whether the increased risk persists. Radiation exposure has been reported to increase a second malignancy in digestive organs (SMDO) in irradiated adult groups 15 . Likewise, results from analysis of the large-scale Childhood Cancer
Survivor Study (CCSS) found that gastrointestinal carcinomas were associated with radiation and alkylating agent therapy 16 . However, very limited data are available on dose-related risks in childhood cancer survivors. The main objective of this population-based case-control study was to estimate the relationship between radiotherapy doses received at a given site in the digestive tract and risk of SMDO at that site, in order to determine the risk conferred by radiation therapy.
METHODS

Study population
French and UK cohort
An initial cohort which included 4 590 2-year survivors of childhood cancer treated in, or before the end of, 1985 at eight cancer centers in France and the UK for all types of FMN (with the exception of leukemia) was created between 1985 and 1995 10 .
A total of 4 568 patients treated before the age of 17 were included. UK patient follow-up was traced using the National Health Service Central Registers 17 .
Follow-up for French patients were assessed using the medical records from the treatment centers, and was also updated from September 1st, 2005 using a selfquestionnaire. This very wide-scale questionnaire provided information on socioeconomic status, cancer risk factors, quality of life and health outcome and was based on that of the BCSS 18 . A total of 2 546 patients who were still alive were considered eligible. A questionnaire was sent by regular mail to the 2 095 patients for whom we had obtained the most recent address from the National Health Insurance
System and who had sent back a signed consent agreement. This agreement included an authorization to contact the medical practitioner and medical facilities. A total of 1 791 (70%) patients returned the completed questionnaire by December 31,
2008.
Cohort study
The cohort study focused exclusively on the French-UK cohort. Results concerning the Nordic cohort had been reported in a previous publication 3 . There were 3 350
French individuals who were followed up until the date of the occurrence of a SMDO, the date of death, the date of response to the self-questionnaire or the date of the last medical contact, whichever occurred first. There were 1 218 British individuals who were followed up through December 2005 until the date of the occurrence of a SMDO or until the date of death, whichever occurred first.
The expected number of SMDO was obtained for each gender, 5-year age group and 5-year calendar period, by multiplying the reference incidence rates by the number of person-years at risk. We used estimates of the French national cancer incidence rates for patients treated at French centers and the United Kingdom national cancer incidence rates for those treated in the UK as reference rates. The standardized incidence ratio (SIR), calculated as the ratio between the observed number of SMDO and the expected number, was considered to follow a Poisson distribution. The annual excess risk (AER) was calculated as the difference between the observed and expected number of SMDO, divided by the number of person-years of follow-up.
AMFIT Software was used for cohort analysis.
Nordic cohort
The Nordic cohort was simply used to provide additional cases and controls for the nested case-control portion of the study. from the Nordic cohort were included. We identified, via a self-questionnaire and medical records, 56 SMDO cases in the French-UK cohort, among whom 42 were included and 14 were excluded for the following reasons: no historical information on deceased patients (n=7), relapse of the initial tumor or metastasis (n=4) and peritoneal tumor (n=3). Finally, 58 cases were included in the present study.
Case-control study
Each case was matched with 3 controls (52 cases), 2 controls (5 cases) and 1 control
(1 case) selected from among all patients from the respective cohort according to sex, age at first cancer (±3 years) and calendar year of occurrence of FMN (±3 years, except for 1 control, diagnosed at +6 years), totaling 167 controls (118 males and 49 females). Controls had to be followed up over a period that was at least equal to the interval between the first and second cancer of the matched case. This period was defined as the follow-up period. and tests were 2-sided.
Radiation dosimetry
Radiotherapy data were obtained from technical radiotherapy records by hospital physicists. Individual doses were calculated with the homemade Dos_EG software package [22] [23] . The local radiation dose was defined as the cumulative absorbed dose at the site of the SMDO for each case, and a similar site for its matched controls.
Since dosimetric reconstruction was not possible for 3 controls, we considered their data as missing in multivariate analysis. To assess the effect of the radiation dose, the local dose was analyzed as a categorized variable (no radiotherapy, <9 Gy, 10-29 Gy, 30 Gy or more).
Chemotherapy measurement
Drugs were classified according to the following categories: epipodophyllotoxins, anthracyclines, alkylating agents, vinca alkaloids, antimetabolites and antibiotics. A detailed description of chemotherapy administered to this cohort has been previously published 24 .
RESULTS
Cohort study
After 102 858 person-years and a median follow-up of 25 years (range, 2 to 63) the risk of a SMDO after initial childhood cancer was 9.7 times greater than that in the general population (95% CI: 7.0 to 12.8), with significantly increased risk of cancers of the stomach, liver, pancreas, colon and rectum ( Table 1 ). The risk of SMDO varied with therapy. Chemotherapy alone and combined modality therapy were associated with a significantly increased risk of developing SMDO (SIR=9.1, 95% CI:
2.3 to 23.6; SIR=29.0, 95% CI: 20.5 to 39.8, respectively). Patients treated with radiotherapy alone had a SIR of 1.0 (CI, 0.2 to 3.0), which was not statistically significant.
The overall AER was 31.5 cases per 100 000 person-years of follow-up (95% CI:
21.0 to 44.7). When the time since diagnosis of the first cancer was taken into account, the SIR decreased (p-trend<.001). In contrast, the AER increased considerably (p-trend <.001) over time following the first cancer, from 2.5 additional cases annually per 100 000 persons between 2 to 10 years after diagnosis, to 116.2 additional cases 40 years or more thereafter (Figure 1 ).
Risk attributable to high radiation doses
In the cohort study, 889 patients (19.5%) had received an average radiation dose to the digestive organs of over 10 Gy, and 22 developed a SMDO. At 35 years or more after treatment, for patients who had received an average dose of less than 10 Gy to the digestive organs, there was a risk of having 126 new cases in excess each year for 100 000 person-years of follow-up (95%CI; 41 to 263); among those who had received more then 10 Gy, the AER was multiplied by 5.8 (AER= 731, 95%CI 293 to 1 450).
Live style risk factors
Of the 1791 patients who sent back the questionnaire, 29% declared themselves as current regular smokers at time of questionnaire, this proportion being 33% in men and 26% in women. The average daily declared consumption of alcohol was 0.80 gram in men and 0.34 in women.
Because only 14 of the 41 cases of SMDO were observed in patients who fulfilled the questionnaire, we were not able to in investigate the role of life style factors in the risk of SMDO.
Case-control study
In 58 cases, nephroblastoma (27.6%), Hodgkin's disease (25.9%) and soft tissue sarcoma (13.8%) were the most frequent FMN, whereas tumors of the colon (41.4%), esophagus and stomach (24.1%) were predominantly SMN. The median age at FMN was 5.4 years, and it was 33.2 years at diagnosis of the SMN ( Table 2) No significant interaction was found between drug categories (coded yes/no) and the local radiation dose.
Overall, in a linear relative risk model, each gray to the digestive organs increased the OR of SMDO of 13% (95%CI: 5% to 32%), this value being non significantly (Chi-2=0.4, p=0.5) different between men (OR=15%, 95%CI: 5% to 35%) and women (OR=8%, 95%CI: -1% to 44%).
DISCUSSION
Our French-UK cohort was at a 9.7-fold increased risk of developing a SMDO compared to the general French-British population. Despite a decrease in the SIR with time since follow-up, a strong increase in AER was observed during the last 40 years of follow-up. In a nested case-control study, we identified a dose-response relationship where in the risk of developing a SMDO or SMDT increased with increasing local radiation doses. This risk was particularly high in patients who had received a radiation dose of 10 Gy or more to the digestive organs. Although chemotherapy was found to increase the risk of developing a SMDO or SMDT, we were unable to find a specific drug or drug category responsible for this increase.
The strong point of this study was that the histology of all cases was validated and the SMDO site considered in each case for the calculation of the local dose was similar to that of matched controls. A major limitation to our study was that we were unable to take into account potential confounding factors such as tobacco and alcohol consumption. Indeed, the risk of various cancers, including those of the upper aerodigestive tract, liver, stomach and colon/rectum, increases with tobacco and alcohol consumption, alone or in combination with dietary habits [25] [26] [27] . However, data on tobacco and alcohol consumption was only available for French patients who completed the self-questionnaire (12 SMDO cases), mostly due to higher mortality for SMDO, 23 SMDO cases had died and thus had not filled in the questionnaire.
Additionally, is has to be noted that childhood cancer survivors in UK 28 and in our cohort (data not shown) have a lower tobacco and alcohol consumption than the general population of their respective country. 16 . These differences might be explained by different follow-up and therapeutic practices since, in hospital-based series like ours, which generally include patients with more extended tumors and more aggressive treatment, there exists a substantially greater risk of SMN than in population-based series 8, 31 .
Up until now, little detailed information has existed on time variations in SIR and AER for digestive cancers. A variation in the temporal pattern similar to ours (the SIR decreased and the AER increased with follow-up) has been observed in adult followed an average of 11 years after Hodgkin's disease 12 . However, the study of 5 925 subjects treated before the age of 21 years for Hodgkin's disease and followed 10.5 years on average, reported increasing SIR and AER which decreased after the age of 40, for all digestive SMN 32 . These observations suggest that risk of SMDO in young adults is increasing and persists throughout the duration of follow up.
In our cohort study, increased risk was found for patients exposed to both radiotherapy and chemotherapy as well as for those treated only with chemotherapy.
Combined radiotherapy has been reported to significantly increase the risk of gastrointestinal cancer in studies on HD adolescents, young adults 33 and adults [12] [13] .
The CCSS study found that risk of gastrointestinal carcinomas (excluding the colon and rectum) after treatment for all cancers was significantly associated with chemotherapy (SIR=7.4) and radiotherapy (SIR=7.0) 16 . In contrast, several HD series did not observe any effect of radiotherapy [12] [13] 33 or chemotherapy [12] [13] 34 .
However, treatment risk is difficult to compare and evaluate, since most reports did not provide detailed information concerning therapeutic exposure.
In our case-control study, we observed significantly increased risk of SMDO with local radiation dose. Interestingly, a similar finding was reported among atomic bomb survivors in Japan, whereas a statistically significant excess risk of cancer of the digestive system was 0.38 for 1 Sivert (95%CI: 0.25 to 0.52) 15 . However, a Nordic study which included 22 cases and 60 controls (16 cases and 42 controls were included in the present study) revealed a significantly increased risk of developing tumors of the digestive tract, including the oral cavity and pharynx, but only for doses of 30 Gy or more (RR=17.6; 95% CI: 2.1 to 148.4) compared to the risk in nonirradiated patients) 19 . In the French-UK cohort, survivors who had received over 10
Gy to the digestive organs during radiotherapy had 731 additional SMDO cases in excess annually per 100 000 person-years of observation 35 years or more after childhood treatment.
Although 71% of the SMDO cases were men, and only 29% women, we were not able to explain this difference. Nevertheless, it has to be noted that, although non significantly, the OR per gray in men was almost 2 times the one in women. Men could be more radiosensitive than women, for various reason including a higher proportion of cofactors such as tobacco and alcohol, that we are unable to investigate in detail.
Although we observed an increased risk of developing SMDO after chemotherapy, the Nordic study did not show this risk increase, probably because of the small number of cases 19 . Due to the frequency and heterogeneity of drug associations in our cohort, we were not able to adequately investigate the role of each drug or type of drug.
In conclusion, longer follow-up in this French-UK cohort showed that cancers of the digestive organs, usually observed in middle-aged adults and the elderly in a general population, occur at a much younger age after childhood cancer treatment and are likely to pose a serious problem for a growing number of long-term cancer survivors.
Elucidating the role of treatments in this increase will require more detailed international pooled analyses. *Multivariate model adjusting to type of first cancer diagnosis. For variables related to radiotherapy, the adjusted OR and p-value estimated controlling for chemotherapy (yes/no). For variables related to chemotherapy, the adjusted and p-value were estimated controlling for local radiation dose (categorized variable). *Multivariate model adjusting to type of first cancer diagnosis. For variables related to radiotherapy, the adjusted OR and p-value estimated controlling for chemotherapy (yes/no).
For variables related to chemotherapy, the adjusted and p-value were estimated controlling for local radiation dose (categorized variable).
